Kura Oncology (KURA) SVP sells shares to cover RSU taxes

Rhea-AI Filing Summary

Kura Oncology, Inc. senior vice president of finance and accounting Thomas James Doyle reported several small sales of common stock on January 27, 2026, each at $8.4607 per share. The transactions were sell-to-cover trades for taxes tied to vesting restricted stock units granted between 2022 and 2025.

After these sales, Doyle beneficially owns 145,167 Kura Oncology common shares directly and an additional 500 shares indirectly through his spouse’s 401(k) account, indicating he retains a substantial equity stake in the company following the tax-related transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOYLE THOMAS JAMES

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & Accounting

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/27/2026		S		2,226	D(1)	$8.4607	150,083	D
Common Stock	01/27/2026		S		1,114	D(2)	$8.4607	148,969	D
Common Stock	01/27/2026		S		695	D(3)	$8.4607	148,274	D
Common Stock	01/27/2026		S		2,226	D(4)	$8.4607	146,048	D
Common Stock	01/27/2026		S		881	D(5)	$8.4607	145,167	D
Common Stock								500	I	spouse's 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/24.

2. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/16/23.

3. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.

4. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/2/25.

5. Sell-to-cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 2/7/22.

	Teresa Bair, Attorney-in-fact for Thomas Doyle	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KURA insider Thomas Doyle report in this Form 4?

Thomas James Doyle reported multiple small sales of Kura Oncology common stock. The trades on January 27, 2026 were to cover taxes from vesting restricted stock units granted between 2022 and 2025, rather than discretionary open-market sales for portfolio rebalancing.

How many KURA shares does Thomas Doyle own after these transactions?

After the reported transactions, Thomas Doyle beneficially owns 145,167 Kura Oncology common shares directly. He also has indirect ownership of 500 additional shares held in his spouse’s 401(k) account, reflecting a continued significant personal equity interest in KURA.

At what price were the KURA shares sold by Thomas Doyle?

Each reported Kura Oncology share sale by Thomas Doyle on January 27, 2026 was executed at a price of $8.4607 per share. These transactions were explicitly described as sell-to-cover trades to satisfy tax obligations arising from vesting restricted stock units.

Why were Thomas Doyle’s KURA stock sales classified as sell-to-cover?

The stock sales were classified as sell-to-cover because they were made to pay taxes on vesting restricted stock units. Footnotes state each sale related to RSUs granted on specific dates from 2022 through 2025, indicating the purpose was tax withholding rather than voluntary share liquidation.

What is Thomas Doyle’s role at Kura Oncology (KURA)?

Thomas James Doyle serves as an officer of Kura Oncology with the title SVP, Finance & Accounting. This senior leadership role means his equity holdings and transactions are subject to public reporting under insider trading disclosure rules for company officers.

Does Thomas Doyle have any indirect ownership of KURA shares?

Yes. In addition to his directly held Kura Oncology shares, Thomas Doyle reports indirect beneficial ownership of 500 common shares. These shares are held in his spouse’s 401(k) account, which is disclosed separately as indirect ownership on the Form 4 filing.